Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decency-RCT: Vancomycin vs Probiotics for C. difficile Prevention
NCT04246151Phase 1Withdrawn
- Sponsor
- Hamilton Health Sciences
- Start
- Sep 2022
- Primary completion
- Sep 2024
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vancomycin and Lactobacillus rhamnosus GG in Clostridium difficile infection (CDI) (3 arms), sponsored by Hamilton Health Sciences. Primary endpoints: Number of patients identified and randomized to a treatment arm within 72 hour of beginning a systematic antibiotic and Development of C difficile associated diarrhea at 14 days. Planned start Sep 2022; status: withdrawn.
02
Drugs
vancomycinLactobacillus rhamnosus GG
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT04246151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04246151.